Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW) "CMB-NOW"

Active, not recruiting

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of NVAF
2. Diagnosis of cerebral infarction or TIA within 2 weeks after onset
3. Patients commenced on NOACs or warfarin therapy as a secondary prevention of cerebral infarction or transient ischemic attack, whether or not anticoagulation therapy was used before enrollment in this study
4. Age ≥20 years and ≤85 years
5. Ability to give valid consent and to provide consent in writing or availability of relatives to provide surrogate consent.
6. At least one CMB detected by 1.5 T MRI (T2*WI) before enrollment in this study

Exclusion Criteria

1. Patients using aspirin or other antiplatelet agents concomitantly
2. Patients in whom NOAC or warfarin is contraindicated
3. Patients with renal dysfunction (CrCL <15 mL/min)
4. Patients with uncontrollable hypertension
5. Patients who are otherwise ineligible to take part in this study as judged by the study doctor